Form 4: BioMarin Director Willard H. Dere Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Director Willard H. Dere reports acquisition of 4,720 restricted stock units in BioMarin Pharmaceutical Inc.
Summary
- On May 21, 2024, Willard H. Dere, a director of BioMarin Pharmaceutical Inc., acquired 4,720 shares of common stock in the form of restricted stock units.
- The acquisition was a direct transaction.
- Following the transaction, Dere directly owns 32,300 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard reporting of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Positives
- The acquisition of restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding the director's stake in the company.
Key Dates
| Date | Description |
|---|---|
| 2023-12-06 | Date of execution for Power of Attorney. |
| 2024-05-21 | Date of transaction: Acquisition of restricted stock units. |
| 2024-05-23 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.